PMC7658551_01
Clinical data of the patient during the treatment. (A) The timeline of treatments for a patient with advanced esophageal squamous carcinoma; (B) CT scans before and after nimotuzumab treatment; (C) Changes in tumor marker levels during treatment.
fonc-10-574523-g001.jpg
PMC7658551_01_fonc-10-574523-g001.jpg
f1
Therefore, the patient came to our hospital and received treatment, the detailed timeline of which is shown in  Figure 1A . TN (nab-paclitaxel + nimotuzumab) regimen, the response was declared a partial response (PR), but after four cycles of this regimen, the patient showed progressive disease (PD). The sizes of two metastatic lesions in the lung increased more than 20% compared with the most recent CT scan (lesion 1: 23%; lesion 2: 24%; average: 23.4%), as shown in  Figure 1B , and the levels of squamous cell carcinoma (SCC) antigen, a tumor marker, rose drastically, as shown in  Figure 1C .